akari
therapeutics
present
phase
ii
data
bullous
pemphigoid
trial
european
academy
dermatology
venereology
eadv
virtual
congress
october
safety
efficacy
data
phase
ii
clinical
trial
nomacopan
adults
mild
moderate
bp
phase
ii
data
basis
agreement
fda
ema
akari
may
proceed
phase
iii
randomised
study
using
nomacopan
treatment
bp
phase
iii
study
europe
expected
begin
nomacopan
granted
orphan
drug
designation
treatment
bp
europe
new
york
london
globe
newswire
akari
therapeutics
plc
nasdaq
aktx
biopharmaceutical
company
focused
innovative
therapeutics
treat
orphan
autoimmune
inflammatory
diseases
complement
leukotriene
systems
implicated
today
announces
presenting
poster
european
academy
dermatology
venereology
eadv
congress
held
virtually
october
november
presentation
posted
onto
akari
website
poster
presentation
describe
safety
efficacy
data
akari
phase
ii
clinical
trial
nomacopan
adult
patients
mild
moderate
bullous
pemphigoid
details
presentation
follows
title
phase
ii
clinical
trial
safety
efficacy
nomacopan
adult
bullous
pemphigoid
patients
phase
ii
clinical
trial
safety
efficacy
nomacopan
adult
bullous
pemphigoid
patients
date
time
october
cet
edt
october
cet
edt
location
eadv
virtual
meeting
registration
required
participate
https
registration
bullous
pemphigoid
bp
bp
severe
orphan
autoimmune
inflammatory
blistering
skin
disease
approved
treatments
europe
disease
elderly
primarily
treated
steroids
immunosuppressants
six
months
plus
bring
deleterious
side
effects
approximately
increase
mortality
bp
treated
population
prevalence
bp
patients
us
europe
bp
patients
evidence
terminal
complement
activation
via
complement
component
lipid
mediator
leukotriene
central
role
driving
disease
ex
vivo
data
bp
patients
published
august
edition
jci
insight
showed
pronounced
accumulation
activation
products
inflamed
skin
bp
patients
underlies
rationale
treatment
nomacopan
unique
bifunctional
inhibitor
range
downstream
cytokines
addition
bp
company
believes
unique
mode
action
underpins
activity
nomacopan
across
company
target
conditions
covid
pneumonia
ophthalmology
well
emerging
clinical
indications
akari
therapeutics
akari
biopharmaceutical
company
focused
developing
inhibitors
acute
chronic
inflammation
specifically
treatment
rare
orphan
diseases
particular
complement
leukotriene
systems
complement
leukotrienes
together
play
primary
role
disease
progression
akari
lead
drug
candidate
nomacopan
formerly
known
coversin
complement
inhibitor
also
independently
specifically
inhibits
leukotriene
activity
cautionary
note
regarding
statements
certain
statements
press
release
constitute
statements
within
meaning
private
securities
litigation
reform
act
place
undue
reliance
upon
company
forward
looking
statements
except
required
law
company
undertakes
obligation
revise
update
statements
order
reflect
event
circumstance
may
arise
date
press
release
statements
reflect
current
views
plans
intentions
expectations
strategies
prospects
based
information
currently
available
us
assumptions
made
although
believe
plans
intentions
expectations
strategies
prospects
reflected
suggested
statements
reasonable
give
assurance
plans
intentions
expectations
strategies
attained
achieved
furthermore
actual
results
may
differ
materially
described
statements
affected
variety
risks
factors
beyond
control
risks
uncertainties
company
include
limited
needs
additional
capital
fund
operations
ability
continue
going
concern
uncertainties
cash
flows
inability
meet
working
capital
needs
inability
delay
obtaining
required
regulatory
approvals
nomacopan
product
candidates
may
result
unexpected
cost
expenditures
ability
obtain
orphan
drug
designation
additional
indications
risks
inherent
drug
development
general
uncertainties
obtaining
successful
clinical
results
nomacopan
product
candidates
unexpected
costs
may
result
therefrom
difficulties
enrolling
patients
clinical
trials
ability
enter
collaborative
licensing
commercial
relationships
terms
commercially
reasonable
us
failure
realize
value
nomacopan
product
candidates
developed
developed
light
inherent
risks
difficulties
involved
successfully
bringing
product
candidates
market
inability
develop
new
product
candidates
support
existing
product
candidates
approval
fda
ema
similar
foreign
regulatory
authorities
competing
superior
products
brought
market
risks
resulting
unforeseen
side
effects
risk
market
nomacopan
may
large
expected
risks
associated
impact
outbreak
coronavirus
risks
associated
sec
investigation
inability
obtain
maintain
enforce
patents
intellectual
property
rights
unexpected
costs
associated
enforcement
litigation
inability
obtain
maintain
commercial
manufacturing
arrangements
third
party
manufacturers
establish
commercial
scale
manufacturing
capabilities
inability
timely
source
adequate
supply
active
pharmaceutical
ingredients
third
party
manufacturers
company
depends
unexpected
cost
increases
pricing
pressures
risks
risk
factors
detailed
public
filings
securities
exchange
commission
including
recently
filed
annual
report
form
filed
sec
except
otherwise
noted
statements
speak
date
press
release
undertake
obligation
update
revise
statements
reflect
events
circumstances
occurring
press
release
caution
investors
place
considerable
reliance
statements
contained
press
release
investor
contact
peter
vozzo
westwicke
media
contact
sukaina
virji
lizzie
seeley
consilium
strategic
communications
akari
